Compare iShares MBS ETF (MBB) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MBS ETF vs State Street SPDR S&P Biotech ETF — how do they compare? iShares MBS ETF trades at $89.79 (market cap $35.41B), while State Street SPDR S&P Biotech ETF trades at $153.75 (market cap $10.11B). The key difference: iShares MBS ETF is far larger — about 3.5× State Street SPDR S&P Biotech ETF's market cap, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, iShares MBS ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares MBS ETF for 96 Days and State Street SPDR S&P Biotech ETF for 38 Days on average.
| MBB | XBI | |
|---|---|---|
Market Cap | $35.41B | $10.11B |
Volume | 5,388,525 | 12,903,266 |
Sector | Fixed Income | Broad Market / Factor |
52-Week High | $96.91 | $169.55 |
52-Week Low | $89.09 | $104.99 |
Typical Hold Time | 96 Days | 38 Days |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MBB (iShares MBS ETF) trades at $89.79, up 0.64% with bearish technical signals from moving averages and ADX indicators. The ETF faces headwinds from rising intermediate-term rates and inflation pressures, with short interest surging 98.3% in September. Recent institutional buying by Corient Private Wealth and Baird Financial contrasts with technical weakness and negative analyst commentary on duration risk.
Outlook remains cautious due to interest rate sensitivity and convexity risks in mortgage-backed securities. The 5.68-year effective duration exposes MBB to Fed policy shifts, though Norway's $2.3 trillion sovereign fund rotation into MBS provides counterbalancing institutional support. Key risks include prepayment optionality and persistent inflation eroding real returns.
XBI trades at $153.75, up 2.34% today, but technical indicators signal a bearish trend with resistance at $154. The ETF's modified equal-weight structure provides exposure to over 150 biotech companies, benefiting from M&A activity and positive clinical catalysts like the Merck-Moderna cancer vaccine breakthrough.
Outlook remains mixed with 100% analyst hold rating contrasting with bullish news catalysts. Key risks include high volatility, sector-specific regulatory pressures, and expense ratios higher than broader healthcare ETFs. The current technical setup near resistance requires monitoring for breakout confirmation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About iShares MBS ETF
The fund will invest at least 80% of its assets in the component securities of the underlying index and TBAs that have economic characteristics that are substantially identical to the economic characteristics of the component securities of the index, and the fund will invest at least 90% of its assets in fixed income securities included in the underlying index that advisor believes will help the fund track the index.
Read more on MBB →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
